Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 1
2002 1
2003 1
2012 1
2014 1
2015 1
2016 2
2017 6
2018 3
2019 4
2020 9
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Results by year
Filters applied: . Clear all
Page 1
Circulating tumor cells: clinical validity and utility.
Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, Bidard FC. Cabel L, et al. Among authors: loirat d. Int J Clin Oncol. 2017 Jun;22(3):421-430. doi: 10.1007/s10147-017-1105-2. Epub 2017 Feb 25. Int J Clin Oncol. 2017. PMID: 28238187 Review.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Adams S, et al. Among authors: loirat d. Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. Ann Oncol. 2019. PMID: 30475950 Free article. Clinical Trial.
Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients.
Núñez NG, Tosello Boari J, Ramos RN, Richer W, Cagnard N, Anderfuhren CD, Niborski LL, Bigot J, Meseure D, De La Rochere P, Milder M, Viel S, Loirat D, Pérol L, Vincent-Salomon A, Sastre-Garau X, Burkhard B, Sedlik C, Lantz O, Amigorena S, Piaggio E. Núñez NG, et al. Among authors: loirat d. Nat Commun. 2020 Jun 29;11(1):3272. doi: 10.1038/s41467-020-17046-2. Nat Commun. 2020. PMID: 32601304 Free PMC article.
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.
Bidard FC, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, Bachelot T, Bourgeois H, Gonçalves A, Ladoire S, Naman H, Dalenc F, Gligorov J, Espié M, Emile G, Ferrero JM, Loirat D, Frank S, Cabel L, Diéras V, Cayrefourcq L, Simondi C, Berger F, Alix-Panabières C, Pierga JY. Bidard FC, et al. Among authors: loirat d. JAMA Oncol. 2021 Jan 1;7(1):34-41. doi: 10.1001/jamaoncol.2020.5660. JAMA Oncol. 2021. PMID: 33151266 Free PMC article.
[Immunotherapies and targeted therapies in medical oncology].
Rousseau B, Champiat S, Loirat D, Arrondeau J, Lemoine N, Soria JC. Rousseau B, et al. Among authors: loirat d. Bull Cancer. 2014 Jan 1;101(1):31-9. doi: 10.1684/bdc.2013.1865. Bull Cancer. 2014. PMID: 24333964 Review. French.
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients.
Rosenbaum P, Artaud C, Bay S, Ganneau C, Campone M, Delaloge S, Gourmelon C, Loirat D, Medioni J, Pein F, Sablin MP, Tredan O, Varga A, Leclerc C. Rosenbaum P, et al. Among authors: loirat d. Cancer Immunol Immunother. 2020 May;69(5):703-716. doi: 10.1007/s00262-020-02503-0. Epub 2020 Feb 7. Cancer Immunol Immunother. 2020. PMID: 32034426 Clinical Trial.
40 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page